IP Library Granted Patent US 8,227,194
Granted Patent B2
US 8,227,194 · App. 11/911,103 · Granted Jul 24, 2012

Monoclonal antibodies with binding specificity for response gene to complement 32 (RGC-32)

Assignee: University of Maryland, Baltimore
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,194
App. No.
11/911,103
Granted
Jul 24, 2012
Kind
B2
Abstract

The invention relates to antibodies that bind to a fragment of the Response Gene to Complement-32 (RGC-32), as well as methods of using these antibodies. Particular methods of using the antibodies of the present invention include, but are not limited to, methods of detecting RGC-32 in a sample, methods of assaying cell proliferation, as well as methods of detecting and/or monitoring the progression of abnormal conditions in a subject, where the disease states are associated with the presence or absence of RGC-32.

Claims (13)

1. An isolated antibody that specifically binds to the amino acid sequence of SEQ ID NO:1, wherein said antibody is a monoclonal antibody.

2. The antibody of claim 1 , wherein said antibody is a single chain antibody.

3. The antibody of claim 1 , wherein said antibody is a single chain Fv (scFv) fragment.

4. The antibody of claim 1 , wherein said antibody is a Fab fragment.

5. The antibody of claim 1 , wherein said antibody is a humanized antibody.

6. The antibody of claim 1 , wherein said antibody is a chimeric antibody.

7. A composition comprising the antibody of claim 1 and a carrier.

8. A method of detecting an antigen in a biological sample, said method comprising contacting said biological sample with the antibody of claim 1 , and detecting the binding of said antibody to said antigen, wherein detectable binding is indicative of the presence of said antigen in said biological sample.

9. The method of claim 8 , wherein said antibody is a single chain antibody.

10. The method of claim 8 , wherein said antibody is a single chain Fv (scFv) fragment.

11. The method of claim 8 , wherein said antibody a Fab fragment.

12. The method of claim 8 , wherein said antibody a humanized antibody.

13. The method of claim 8 , wherein said antibody a chimeric antibody.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2011
From: RUS, HOREA; FOSBRINK, MATTHEW; BADEA, TUDOR
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 026841/0917 →
CONFIRMATORY LICENSE Recorded Mar 4, 2011
From: HOREA RUS, M D, PH D
To: DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 025908/0251 →
CONFIRMATORY LICENSE Recorded May 22, 2008
From: UNIVERSITY OF MARYLAND, BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020985/0283 →
Continuity (2)
Provisional Application 60669463 · Apr 8, 2005
Related Publication 20110034344A1 · Feb 10, 2011